Nilotinib within its licensed indication for the first line treatment of chronic myeloid leukaemia
Status Discontinued
Decision Selected
Process STA pre-2018
Referral date 01 March 2009
Topic area
  • Cancer

Cancer reform strategy Batch 4

Provisional Schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC

Project Team

Communications manager: TBC
Executive Lead: Peter Littlejohns
Project manager: TBC
Technical Lead: Joao Vieria


Key events during the development of the guidance:

Date Update
6 August 2010

Nilotinib for the first line treatment of chronic myeloid leukaemia was referred to NICE as a Single Technology Appraisal (STA).

NICE have recently undertaken a draft scope consultation exercise and held a scoping workshop for the proposed appraisal of dasatinib for the first line treatment of chronic myeloid leukaemia. As a result of this work, the Department of Health has now asked NICE to carry out a multiple technology appraisal of dasatinib, nilotinib and standard-dose imatinib within their licensed indications for the first-line treatment of chronic myeloid leukaemia (including part-review of TA70) as part of our 24th wave work programme.

Therefore nilotinib will not be appraised through the STA process.

For further information on our processes and methods, please see our CHTE processes and methods manual